Christopher T Rentsch, PhD, FISPE
Assistant Professor AdjunctCards
About
Research
Publications
2024
Severe Acute Liver Injury After Hepatotoxic Medication Initiation in Real-World Data
Torgersen J, Mezochow A, Newcomb C, Carbonari D, Hennessy S, Rentsch C, Park L, Tate J, Bräu N, Bhattacharya D, Lim J, Mezzacappa C, Njei B, Roy J, Taddei T, Justice A, Re V. Severe Acute Liver Injury After Hepatotoxic Medication Initiation in Real-World Data. JAMA Internal Medicine 2024, 184: 943-952. PMID: 38913369, PMCID: PMC11197444, DOI: 10.1001/jamainternmed.2024.1836.Peer-Reviewed Original ResearchIncidence rateUS Department of Veterans AffairsMedication initiationDepartment of Veterans AffairsInitiation of medicationVeterans AffairsMain OutcomesPotential of medicationsOutpatient settingDischarge diagnosisCohort studyDay of admissionCase reportReal World DataReport countsMedicationMedical cohortSevere acute liver injuryUS DepartmentFollow-upAcute liver injuryHospitalCohortHepatotoxic medicationsIncidenceContribution of Potentially Inappropriate Medications to Polypharmacy-Associated Risk of Mortality in Middle-Aged Patients: A National Cohort Study
Guillot J, Justice A, Gordon K, Skanderson M, Pariente A, Bezin J, Rentsch C. Contribution of Potentially Inappropriate Medications to Polypharmacy-Associated Risk of Mortality in Middle-Aged Patients: A National Cohort Study. Journal Of General Internal Medicine 2024, 1-10. PMID: 38831248, DOI: 10.1007/s11606-024-08817-4.Peer-Reviewed Original ResearchMiddle-aged patientsRisk of mortalityVeterans AffairsChronic medicationsVA patient populationIntegrated healthcare systemNational cohort studyAssociated with increased mortalityMiddle-aged individualsMechanism of injuryMiddle-aged peopleAssociated with mortalityInappropriate medicationsBeers criteriaHealthcare systemAttenuate riskCohort studyClinical characteristicsGeneral populationHyperpolypharmacyFollow-upPolypharmacyPatient populationBackgroundThe roleCox modelOpenSAFELY: A platform for analysing electronic health records designed for reproducible research
Nab L, Schaffer A, Hulme W, DeVito N, Dillingham I, Wiedemann M, Andrews C, Curtis H, Fisher L, Green A, Massey J, Walters C, Higgins R, Cunningham C, Morley J, Mehrkar A, Hart L, Davy S, Evans D, Hickman G, Inglesby P, Morton C, Smith R, Ward T, O'Dwyer T, Maude S, Bridges L, Butler‐Cole B, Stables C, Stokes P, Bates C, Cockburn J, Hester F, Parry J, Bhaskaran K, Schultze A, Rentsch C, Mathur R, Tomlinson L, Williamson E, Smeeth L, Walker A, Bacon S, MacKenna B, Goldacre B. OpenSAFELY: A platform for analysing electronic health records designed for reproducible research. Pharmacoepidemiology And Drug Safety 2024, 33: e5815-e5815. PMID: 38783412, PMCID: PMC7616137, DOI: 10.1002/pds.5815.Peer-Reviewed Original ResearchConceptsElectronic health recordsHealth recordsComputing environmentProgram codeSoftware platformAdministrative health dataAnalysis environmentAudit trailReproducibility of researchReproducible researchData preparationPublic sharingPublic health guidanceHealth dataHealth guidanceCodeOpenSAFELYTechnical solutionsPlatformPromote trustCOVID-19 pandemicIncrease transparencyCode-sharingWorkflowDataCare interruptions and mortality among adults in Europe and North America
Trickey A, Zhang L, Rentsch C, Pantazis N, Izquierdo R, Antinori A, Leierer G, Burkholder G, Cavassini M, Palacio-Vieira J, Gill M, Teira R, Stephan C, Obel N, Vehreschild J, Sterling T, Van Der Valk M, Bonnet F, Crane H, Silverberg M, Ingle S, Sterne J. Care interruptions and mortality among adults in Europe and North America. AIDS 2024, 38: 1533-1542. PMID: 38742863, PMCID: PMC11239093, DOI: 10.1097/qad.0000000000003924.Peer-Reviewed Original ResearchCare interruptionsMortality riskCohort studyHazard ratioAnalysis of cohort studiesAntiretroviral therapyCare of peopleRobust to sensitivity analysesMortality hazard ratioCrude mortality rateHazard of mortalityAntiretroviral therapy initiationObservational cohort studyAntiretroviral therapy startUninterrupted careFollow-up groupCareAssociated with adverse outcomesPWHCox regressionAdverse outcomesFollow-up timeMortality rateCompare hazardsComposite outcomeAuthor Correction: A multi-ancestry genetic study of pain intensity in 598,339 veterans
Toikumo S, Vickers-Smith R, Jinwala Z, Xu H, Saini D, Hartwell E, Pavicic M, Sullivan K, Xu K, Jacobson D, Gelernter J, Rentsch C, Stahl E, Cheatle M, Zhou H, Waxman S, Justice A, Kember R, Kranzler H. Author Correction: A multi-ancestry genetic study of pain intensity in 598,339 veterans. Nature Medicine 2024, 30: 2088-2088. PMID: 38714900, DOI: 10.1038/s41591-024-03024-4.Peer-Reviewed Original ResearchQuantifying possible bias in clinical and epidemiological studies with quantitative bias analysis: common approaches and limitations
Brown J, Hunnicutt J, Ali M, Bhaskaran K, Cole A, Langan S, Nitsch D, Rentsch C, Galwey N, Wing K, Douglas I. Quantifying possible bias in clinical and epidemiological studies with quantitative bias analysis: common approaches and limitations. The BMJ 2024, 385: e076365. PMID: 38565248, DOI: 10.1136/bmj-2023-076365.Peer-Reviewed Original ResearchA multi-ancestry genetic study of pain intensity in 598,339 veterans
Toikumo S, Vickers-Smith R, Jinwala Z, Xu H, Saini D, Hartwell E, Pavicic M, Sullivan K, Xu K, Jacobson D, Gelernter J, Rentsch C, Stahl E, Cheatle M, Zhou H, Waxman S, Justice A, Kember R, Kranzler H. A multi-ancestry genetic study of pain intensity in 598,339 veterans. Nature Medicine 2024, 30: 1075-1084. PMID: 38429522, DOI: 10.1038/s41591-024-02839-5.Peer-Reviewed Original ResearchPain intensityChronic painTreat chronic painCalcium channel blockersCross-ancestry meta-analysisGenome-wide association studiesExperience of painSamples of European ancestryPain phenotypesFunctional genomics dataGABAergic neuronsCalcium channelsAnalgesic effectB-blockersDrug groupMillion Veteran ProgramPainSubstance use disordersQuality of lifeDrug repurposing analysisOpioid crisisGenetic architectureCausal genesGenetic lociGenomic dataIncident dementia risk among patients with type 2 diabetes receiving metformin versus alternative oral glucose-lowering therapy: an observational cohort study using UK primary healthcare records
Doran W, Tunnicliffe L, Muzambi R, Rentsch C, Bhaskaran K, Smeeth L, Brayne C, Williams D, Chaturvedi N, Eastwood S, Dunachie S, Mathur R, Warren-Gash C. Incident dementia risk among patients with type 2 diabetes receiving metformin versus alternative oral glucose-lowering therapy: an observational cohort study using UK primary healthcare records. BMJ Open Diabetes Research & Care 2024, 12: e003548. PMID: 38272537, PMCID: PMC10823924, DOI: 10.1136/bmjdrc-2023-003548.Peer-Reviewed Original ResearchConceptsRisk of dementiaMild cognitive impairmentOral glucose-lowering therapyDementia riskObservational cohort studyAs-treated analysisGlucose-lowering therapyRisk of incident all-cause dementiaUK adultsCompare risk of dementiaIncident all-cause dementiaType 2 diabetesClinical Practice Research DatalinkActive comparator new user designCohort studyAll-cause dementiaPrimary healthcare recordsIncident dementia riskAssociated with lower riskPotential exposure misclassificationCox proportional hazards regressionMetformin useRisk of confoundingProportional hazards regressionIncident dementiaPsychotropic prescribing after hospital discharge in survivors of critical illness, a retrospective cohort study (2012–2019)
Mansi E, Rentsch C, Bourne R, Guthrie B, Lone N. Psychotropic prescribing after hospital discharge in survivors of critical illness, a retrospective cohort study (2012–2019). Journal Of The Intensive Care Society 2024, 25: 171-180. PMID: 38737305, PMCID: PMC11081855, DOI: 10.1177/17511437231223470.Peer-Reviewed Original ResearchPsychotropic prescriptionsSurvivors of critical illnessCritical care survivorsPsychotropic prescribingCare groupHospital dischargeRetrospective cohort studyCritical careCritical illnessCohort studyHazard ratioMental health issuesCritical care groupHospitalised survivorsPsychotropic medicinesPotential confoundersSleep disturbanceHospitalised adultsHealth issuesHospitalised patientsIllnessSurvivorsPrescriptionClinical practiceCareHypertension Control During the Coronavirus Disease 2019 Pandemic
Korves C, Peixoto A, Lucas B, Davies L, Weinberger D, Rentsch C, Vashi A, Young-Xu Y, King J, Asch S, Justice A. Hypertension Control During the Coronavirus Disease 2019 Pandemic. Medical Care 2024, 62: 196-204. PMID: 38284412, PMCID: PMC10922611, DOI: 10.1097/mlr.0000000000001971.Peer-Reviewed Original ResearchConceptsHypertension controlFollow-up intervalPrimary care clinic visitsFollow-up lengthVeterans Health AdministrationControlled hypertensionUncontrolled hypertensionGeneralized estimating equationsCohort of individualsStudy inclusion criteriaHealth careHealth AdministrationLonger follow-up intervalsBlood pressure measurementsAssessed associationsClinic visitsInclusion criteriaDecreased likelihoodEstimating equationsPrepandemic periodLow likelihoodCoronavirus diseaseFollow-upHypertensionIndividuals
Academic Achievements & Community Involvement
News & Links
News
- March 11, 2024
Excess Deaths During the COVID-19 Pandemic
- February 02, 2023Source: NIH National Institute on Drug Abuse Intramural Research Program
Spironolactone as a potential new pharmacotherapy for alcohol use disorder: convergent evidence from rodent and human studies
- August 11, 2021
Congratulations to New Department Faculty! (August 2021)
- February 25, 2021Source: Forbes
Should Anticoagulants Be Used Early Or Late In Patients Hospitalized With Covid-19: Two Conflicting Answers